Search research articles
Contact Us
Filters
Showing results (121-130 of 132) with videos related to
Page
of 14
Sort By:
Biorxiv : the Preprint Server for Biology
|
December 9, 2024
Replication stress marker phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination-proficient ovarian cancer
Angela Schab, Amanda Compadre, Rikki Drexler, et al.
Cancer Research Communications
|
May 21, 2026
Interleukin-34 induced Arg1+ macrophages play a key role in breast cancer brain metastasis
Xiaoqing Cheng, Khooshbu K Patel, Brandon Zhou, et al.
NPJ Breast Cancer
|
December 30, 2022
A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013
Foluso O Ademuyiwa, Feng Gao, Cherease R Street, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 7, 2017
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i>-Mutant ER-Positive and HER2-Negative Breast Cancer
Cynthia X Ma, Vera Suman, Matthew P Goetz, et al.
Biorxiv : the Preprint Server for Biology
|
August 13, 2025
Targeting the COP9 signalosome overcomes platinum resistance in ovarian cancer through two distinct genome stability mechanisms
Elena Lomonosova, Megan Loeb, Kevin Rodriguez, et al.
Nature Communications
|
January 27, 2026
Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial
Tim Kong, Alex Mabry, Maureen Highkin, et al.
Genome Medicine
|
November 14, 2024
Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients
Xiuli Zhang, S Peter Goedegebuure, Michael Y Chen, et al.
Breast Cancer Research and Treatment
|
June 26, 2021
Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer
Foluso O Ademuyiwa, Ina Chen, Jingqin Luo, et al.
The Journal of Molecular Diagnostics : JMD
|
November 12, 2013
Validation of a next-generation sequencing assay for clinical molecular oncology
Catherine E Cottrell, Hussam Al-Kateb, Andrew J Bredemeyer, et al.
Cancer Discovery
|
August 24, 2022
Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer
Meenakshi Anurag, Eric J Jaehnig, Karsten Krug, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 132) with videos related to
Sort By:
Page
of 14
Biorxiv : the Preprint Server for Biology
|
December 9, 2024
Replication stress marker phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination-proficient ovarian cancer
Angela Schab, Amanda Compadre, Rikki Drexler, et al.
Cancer Research Communications
|
May 21, 2026
Interleukin-34 induced Arg1+ macrophages play a key role in breast cancer brain metastasis
Xiaoqing Cheng, Khooshbu K Patel, Brandon Zhou, et al.
NPJ Breast Cancer
|
December 30, 2022
A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013
Foluso O Ademuyiwa, Feng Gao, Cherease R Street, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 7, 2017
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i>-Mutant ER-Positive and HER2-Negative Breast Cancer
Cynthia X Ma, Vera Suman, Matthew P Goetz, et al.
Biorxiv : the Preprint Server for Biology
|
August 13, 2025
Targeting the COP9 signalosome overcomes platinum resistance in ovarian cancer through two distinct genome stability mechanisms
Elena Lomonosova, Megan Loeb, Kevin Rodriguez, et al.
Nature Communications
|
January 27, 2026
Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial
Tim Kong, Alex Mabry, Maureen Highkin, et al.
Genome Medicine
|
November 14, 2024
Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients
Xiuli Zhang, S Peter Goedegebuure, Michael Y Chen, et al.
Breast Cancer Research and Treatment
|
June 26, 2021
Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer
Foluso O Ademuyiwa, Ina Chen, Jingqin Luo, et al.
The Journal of Molecular Diagnostics : JMD
|
November 12, 2013
Validation of a next-generation sequencing assay for clinical molecular oncology
Catherine E Cottrell, Hussam Al-Kateb, Andrew J Bredemeyer, et al.
Cancer Discovery
|
August 24, 2022
Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer
Meenakshi Anurag, Eric J Jaehnig, Karsten Krug, et al.
Page
of 14